Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Phillips 66 — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while Phillips 66 trades at $186.5 (market cap $71.70B). The key difference: Phillips 66 is far larger — about 16× ACADIA Pharmaceuticals Inc.'s market cap, and Phillips 66 pays a 2.84% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | PSX | |
|---|---|---|
Market Cap | $4.49B | $71.70B |
Sector | Health | Energy |
52-Week High | $28.06 | $188.28 |
52-Week Low | $20.06 | $118.37 |
Enterprise Value | $3.69B | $93.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Phillips 66 (PSX) trades at $178.84, up 1.37% with a bullish technical signal and strong analyst consensus. The stock shows improving fundamentals with recent earnings beats, a 3.07% net margin, and attractive valuation at P/E 17.52 and P/S 0.54. Recent news highlights resilience amid softer oil prices, supported by diversified operations and a $1.27 dividend payment.
Outlook remains positive with a $190.38 price target, though risks include refining volatility from Hormuz disruptions and declining revenue trends. The stock offers value through stable cash flow and dividend income, but investors should monitor geopolitical impacts on earnings and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
